Psychemedics Co. (NASDAQ:PMD) Major Shareholder Buys $19,355.07 in Stock

Psychemedics Co. (NASDAQ:PMD) major shareholder Powell Anderson Capital Partne acquired 7,473 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was acquired at an average price of $2.59 per share, with a total value of $19,355.07. Following the transaction, the insider now owns 415,038 shares in the company, valued at approximately $1,074,948.42. The trade was a 1.83 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Powell Anderson Capital Partne also recently made the following trade(s):

• On Thursday, December 12th, Powell Anderson Capital Partne bought 75,000 shares of Psychemedics stock. The shares were purchased at an average price of $2.67 per share, with a total value of $200,250.00.

Psychemedics Trading Down 1.8 %

PMD stock opened at $2.67 on Friday. The company has a market cap of $15.73 million, a P/E ratio of -5.24 and a beta of 0.65. Psychemedics Co. has a twelve month low of $1.63 and a twelve month high of $3.93. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $2.38 and a 200-day moving average of $2.31.

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.